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1. Introduction
Constipation is a commonly diagnosed gastrointestinal 
disorder with an estimated prevalence of 12-19% in the 
general population (Higgins and Johanson, 2004; Locke 
et al., 2000). Females and the elderly are at increased 
risk for constipation (Harris, 2005). Constipation results 
in lower quality of life and significant healthcare costs 
to the individual (Belsey et al., 2010). The diagnosis of 
functional constipation and constipation-predominant 
irritable bowel syndrome (IBS-C) are based on similar 
symptoms, with IBS-C also being associated with abdominal 
pain or discomfort (Longstreth et al., 2006). The cause of 
constipation is often unknown and likely multifactorial 
with physiological changes, psychological factors, and 
lifestyle influences identified as possible sources. The initial 
management of constipation-related symptoms is focused 
on evaluating lifestyle and diet variables as possible causes. 
If lifestyle modifications are unsuccessful in alleviating 
constipation, various medications may be prescribed. 
However, overall these medications have limited efficacy, 
are expensive, and may result in side effects, especially 
over long-term use. Thus, there is a need for alternative 
constipation treatments that are safe, effective, and cost-
effective.
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Abstract
Selected strains of lactobacilli and bifidobacteria are known to ameliorate constipation-related symptoms and 
have previously shown efficacy on digestive health. In this clinical trial, the safety and effectiveness of a probiotic 
blend containing lactobacilli and bifidobacteria were evaluated in adults with self-reported bloating and functional 
constipation. Constipation was diagnosed by the Rome III criteria. A total of 156 adults were randomised into this 
double-blind and placebo-controlled trial. Participants consumed the combination of Lactobacillus acidophilus 
NCFM (1010 cfu), Lactobacillus paracasei Lpc-37 (2.5×109 cfu), Bifidobacterium animalis subsp. lactis strains Bl-04 
(2.5×109 cfu), Bi-07 (2.5×109 cfu) and HN019 (1010 cfu) (n=78), or placebo (microcrystalline cellulose) (n=78) for two 
weeks. After treatment the following were measured: primary outcome of bloating and secondary outcomes of colonic 
transit time, bowel movement frequency, stool consistency, other gastrointestinal symptoms (flatulence, abdominal 
pain, and burbling), constipation-related questionnaires (PAC-SYM and PAC-QoL) and product satisfaction. Faecal 
recovery of consumed strains was determined. The enrolled population was defined as constipated, however, the 
initial bloating severity was lower than in previous similar studies. No clinically significant observations related to 
the safety of the product were reported. Product efficacy was not shown in the primary analysis for bloating nor for 
the secondary efficacy analyses. The placebo functioned similarly as the probiotic product. In post-hoc analysis, a 
statistically significant decrease in flatulence in favour of the probiotic group was observed; day 7 (intention-to-treat 
(ITT): P=0.0313; per-protocol (PP): 0.0253) and on day 14 (ITT: P=0.0116; PP: P=0.0102) as measured by area under 
the curve (AUC) analysis. The mean AUC of all symptoms decreased in favour of the probiotic group, indicating 
less digestive discomfort. The study was registered at the ISRCTN registry (ISRCTN41607808).
Keywords: bifidobacteria, CTT, flatulence, lactobacilli, transit
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Bloating, as a subjective feeling of increased pressure 
within the abdomen, is a bothersome symptom possibly 
related to slowed transit, increased faecal mass in the colon 
and/or gas-production by the gut microbiota (Iovino et 
al., 2014). A third of the general population and almost 
all IBS patients suffer from bloating (Longstreth et al., 
2006). In a large survey conducted in the USA on bowel 
symptoms among individuals with IBS-C and those with 
functional constipation, the subjective feeling of bloating 
was encountered 2.8 and 1.4 times a week (respectively) 
and approximately every second individual considered 
bloating to be a very or extremely bothersome symptom 
(Heidelbaugh et al., 2015). Gastrointestinal illnesses may be 
associated with variance of or abnormalities in whole-gut 
or colonic transit time (CTT); for example, constipation is 
associated with an abnormally slow CTT, which in healthy 
individuals has been reported as having an average 30-40 
hours but can range up to 70 hours (Bautista Casasnovas 
et al., 1991; Kim and Rhee, 2012; Metcalf et al., 1987). The 
severity of bloating is known to correlate positively with 
prolonged CTT (Raahave et al., 2009). Thus, bloating may 
perform as a slow-transit-related symptom in constipation 
that can be affected by microbiota-targeting interventions 
and measured as a subjective feeling essential to the quality 
of life of the individual.
In recent years, probiotics (Fao/Who, 2001; Hill et al., 
2014) have been commonly used to alleviate symptoms in 
a variety of gastrointestinal disorders. It is hypothesised 
that probiotics help to maintain gut lumen homeostasis by 
suspending the growth of luminal pathogens and restoring 
the normal flora of the gut. As such, the use of probiotics 
for the relief of constipation-related symptoms, including 
bloating, is very promising. Numerous studies and meta-
analyses have been published addressing the utility of 
probiotics for gastrointestinal health including constipation 
(Miller et al., 2017c; Miller et al., 2016). However, since 
probiotic efficacy is largely strain-specific, each specific 
strain must be individually tested in clinical trials.
The intestine has a complex population of beneficial bacteria 
which are essential for the host health including nutrient 
and vitamin availability and functional immunity (Turroni 
et al., 2014). Bacteria from the genera Bifidobacterium and 
Lactobacillus are commonly found in the intestinal gut of 
humans and increasingly used in food and pharmaceutical 
applications to balance disturbed intestinal microflora 
and related dysfunction of the gastrointestinal tract. 
Selected strains of lactobacilli and bifidobacteria have 
traditionally been considered probiotics (Fao/Who, 2001; 
Hill et al., 2014) and several lactobacilli and bifidobacteria 
strains have previously shown efficacy in digestive health. 
Lactobacillus acidophilus NCFM (NCFM) has been 
reported to modulate mu-opioid receptor expression and 
activity – linked to reduced visceral pain – in clinical and 
preclinical trials (Ringel-Kulka et al., 2014; Rousseaux et 
al., 2007). Lactobacillus paracasei Lpc-37 (Lpc-37) has 
been shown to reduce diarrhoea incidence in children 
(Hemalatha et al., 2014). Bifidobacterium animalis subsp. 
lactis Bi-07 (Bi-07) has shown reduced diarrhoea incidence 
in toddlers, in addition to alleviation of constipation in 
adults (Bettler et al., 2006; Favretto et al., 2013). Studies 
with B. animalis subsp. lactis HN019 (HN019) have shown 
reduced diarrhoea incidence in children, reduced CTT 
and bowel symptoms (Dekker et al., 2009; Hemalatha et 
al., 2014; Waller et al., 2011). When administered together 
with a prebiotic fibre, polydextrose, NCFM and Bi-07 have 
been able to reduce CTT (Magro et al., 2014). While the 
combination of NCFM, Lpc-37, Bi-07 and B. animalis 
subsp. lactis Bl-04 (Bl-04) has been reported to reduce the 
incidence and duration of antibiotic associated diarrhoea 
and side effects of antibiotic use (Ouwehand et al., 2014).
Given the promising clinical results of probiotics on 
gastrointestinal health to date, the objective of the current 
clinical trial was to evaluate the safety and effectiveness of a 
two-week supplementation of a probiotic blend containing 
selected strains of lactobacilli and bifidobacteria on bloating, 
CTT and other gastrointestinal symptoms in adults with 
self-reported bloating and constipation.
2. Materials and methods
Study design
This was a two-centre, randomised, double-blind, placebo-
controlled, parallel-group, phase II study with two treatment 
arms. The study was conducted to determine the safety and 
efficacy of a two-week supplementation of a probiotic blend 
on abdominal bloating severity and other gastrointestinal 
parameters in an otherwise healthy adult population 
suffering from bloating and constipation. The study was 
conducted per globally accepted standards of good clinical 
practice (ICH, 1996), in agreement with the Declaration 
of Helsinki (WMA, 2013), and in accordance with local 
regulations for clinical research (additional Ethics and good 
clinical practice description in Supplementary Materials and 
methods). The primary outcome was subjective assessment 
of bloating incidence and severity. Secondary outcomes 
were CTT, defecation frequency, stool consistency, 
subjective assessment of constipation-related digestive 
symptoms in addition to bloating (flatulence, abdominal 
pain, and burbling), constipation-related questionnaires, 
and overall product satisfaction. Faecal microbial analysis 
was conducted for determining the product recovery. The 
study design is presented in Figure 1.
The eligible volunteers were adult participants aged 
between 18 to 70 years with functional constipation (FC) or 
IBS-C as per Rome III criteria (Drossman, 2006; Longstreth 
et al., 2006), bowel movement frequency 1-3/week, stool 
consistency 1-2 according to the Bristol Stool Scale (BSS) 
Please cite this article as 'in press'  Beneficial Microbes 
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Form (Lewis and Heaton, 1997) for most spontaneously 
passed stools, and self-reported bloating at least twice a 
week. Although FC and IBS-C are different populations, we 
decided to combine these as this would cover self-reported 
constipation, which was studied earlier (Waller et al., 2011). 
Detailed exclusion criteria are provided in supplemental 
material.
In total, 264 participants were pre-screened and 263 were 
enrolled after being fully informed and giving signed 
consent. The study consisted of a screening visit, a two-
week run-in period, and a two-week on-treatment period. 
Participants who passed the initial screening and met the 
inclusion and exclusion criteria entered the run-in period. 
At screening, participants were given an android tablet 
computer with the electronic diary (eDiary) app (Mobanode, 
Limerick, Ireland), which included symptom survey, 
product compliance, and bowel movement frequency and 
stool consistency questions. During the run-in period, 
participants recorded relevant study data every day in the 
eDiary. After the first week of run-in (day -14 to day -7) the 
eligibility of the participants was re-assessed and those who 
met the inclusion criteria, continued in the study and were 
given radio opaque markers (ROMs) to be consumed daily 
for 6 days (day -6 to day -1). Participants who successfully 
completed the run-in period (including 100% compliance 
with ROM consumption, and 100% compliance with daily 
diary completion for stool frequency and consistency, 
and digestive symptoms) were randomised to receive 
the supplementation with either the active product or 
placebo (for composition see Supplementary Materials 
and methods).
Study procedure
Participants were randomised on a 1:1 basis to receive 
either the active probiotic blend or matching placebo. 
Randomisation was carried out by computer-generated 
block-randomisation lists. Participants were randomised 
to one of the two treatment groups in equal proportions. 
The block sizes varied randomly (4, 6, and 8). The 
randomisation was also seeded, with the seed only available 
to the statistician generating the randomisation list. 
The randomisation was provided by the statistician in 
a password-protected file. Danisco USA (Madison, WI, 
USA) produced, packaged, and labelled the investigational 
product (IP) according to the study code and treatment 
assignment following a strict double-blind procedure. All 
product dispensing occurred at the Atlantia Food Clinical 
Trials Ltd. study site in Blackpool, Cork, Ireland. All 
participants, site support staff, and investigators remained 
blinded to the product identity and group allocation. The 
study product was assigned to participants in chronological 
order. Detailed IP information provided in supplemental 
methods.
Participants were instructed to take one dose of study 
product per day, with breakfast, and to store the IP in a 
refrigerator (2-8 °C). Participants recorded their product 
consumption throughout the study in the eDiary. The time 
of administration of dosing was not recorded. At Visit 
5 (day 14 of dosing), each participant was to return the 
completed eDiary and all unconsumed products, if any. 
Product compliance was assessed by calculating the number 
of returned capsules.
Run-in On-treatment
Baseline Treatment
Visit 1
Day -14
Visit 2
Day -6
Visit 3
Day 0
Visit 4
Day 8
Visit 5
Day 14
Informed consent
Inclusion/exclusion criteria
eDiary run-In
ROMs consumption
Abdominal X-ray
Randomisation
Treatment
eDiary intervention
Stool sample collection
Questionaires
Product satisfaction
Figure 1. The study design and set-up. The following terms for different study periods were defined in the statistical analyses 
plan: run-in (day -14 to day -1), on-treatment (day 0 to day 13), baseline (day -7 to day -1) and treatment (day 7 to day 13). ROM 
= radio-opaque marker.
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In addition, gastrointestinal symptom severity, defecation 
frequency and stool consistency were recorded daily in the 
eDiary, the international short self-administered physical 
activity questionnaire (Hagstromer et al., 2006), covering 
the last 7 days, was assessed at the clinic at day 0 and 14, 
and EPIC-Norfolk food frequency questionnaire (FFQ) 
(Bingham et al., 2001) was assessed once during the trial 
(day 0) to check for eligibility. The overall satisfaction 
with the study product’s ability to relieve the constipation 
symptoms was assessed at day 14. A visit window of ±1 day 
was provided to the participants to add flexibility.
Safety assessment
Safety of the participants during the intervention was 
evaluated by adverse event (AE) enquiry during the 
weekly visits to the clinic (day 0, 8 and 14). The nature and 
frequency of AEs and serious adverse events (SAEs) were 
followed throughout the trial. The primary safety analysis 
was based on the frequency and severity of AEs. Absolute 
and relative frequencies of the number of AEs were reported 
for the categories: any, serious, by intensity, by relationship 
to study product, by action taken, and by outcome. SAEs 
were to be analysed similarly. The secondary safety analysis 
was based on vital signs and the clinical significance of the 
following variables: body temperature (ear, °C); systolic 
blood pressure (mmHg); diastolic blood pressure (mmHg); 
heart/pulse rate (beats/minute); height (cm); weight (kg); 
and body mass index (kg/m2). The clinically significant 
findings of the vital signs were reported as frequency 
distributions and percentages.
Subjective assessment of constipation-related digestive 
symptoms
The primary efficacy variable was the change in average 
visual analogue scale (VAS) score for abdominal bloating 
in the second week of the intervention period (day 7 to 
13). The change in average VAS scores from the Baseline 
period (day -7 to 1) to the so-called treatment period (day 
7 to 13), controlling for baseline, were compared between 
the active and placebo groups. Participant assessment of 
bloating was measured each day during the run-in (day -14 
to -1) and on-treatment (day 0 to 14) periods using a VAS 
scored from 0 to 100 in a similar manner to that used for 
individual symptoms scores in the IBS-symptom severity 
score (Francis et al., 1997) and results were recorded in 
the eDiary. The average VAS was calculated as a sum of 
VAS scores (mm) divided by the number of days with VAS 
score data. The secondary outcomes for other constipation-
related digestive symptoms in addition to bloating were 
flatulence, abdominal pain, and burbling. These digestive 
symptoms were reported as average VAS measured over the 
second week of intervention period (day 7 to 13), similarly 
to the primary outcome for bloating.
Colonic transit time
CTT was assessed using abdominal X-rays on day 0 and 
14. Each participant ingested 20 ROMs each day for six 
consecutive days prior to the abdominal X-ray days. 
Participants were to ingest a total amount of 120 markers 
during the run-in period (day -6 to -1) and another 120 
markers during the on-treatment period (day 8 to 13). 
Marker counts were identified by a radiologist who 
remained blinded to treatment assignment. CTTs were 
calculated according to the distribution of the ROMs in 
different segments – ascending colon, transverse colon and 
distal to the splenic flexure – of the bowel and summed to 
yield a total marker count. CTT was calculated using the 
classic film estimate as described in the following formula:
CTT = ni × (t/N)
where ni is the number of ROMs observed on X-ray, t is the 
time between marker ingestions in hours, and N is the total 
number of ROMs ingested each day (Bouchoucha et al., 
1992; Bouchoucha et al., 2006; Bouchoucha and Thomas, 
2000). The ROMs were to be administered off-site, daily, 
at the same time each day, and the participants filmed 
themselves swallowing the markers to ensure compliance.
Defecation frequency and stool consistency
Participants recorded the number of defecations per day 
in the daily eDiary during the run-in period and during 
the two-week intervention period. Participants also 
recorded stool consistency from each defecation event. 
Stool consistency was rated in the eDiary using the BSS 
form (Lewis and Heaton, 1997).
PAC-SYM and PAC-QoL questionnaires
Participant assessment of constipation-related symptoms 
(PAC-SYM) and participant assessment of constipation-
related quality of life (PAC-QoL) were evaluated at the 
clinic with PAC-SYM (Standard Version 2.0-Sd, 12-
item) and PAC-QoL (Standard Version 2.0-Sd, 28-item) 
questionnaires at baseline (day 0) and at the end of the 
intervention (day 14) on a 5-point Likert scale (from 0 to 4) 
(Frank et al., 1999; Lembo et al., 2010; Marquis et al., 2005).
Faecal microbial analysis for multi-strain product 
recovery
Faecal samples were collected from the participants at 
baseline (within day -6 until 0) before IP consumption, and 
at the end of the intervention period (within day 8 until 
14). DNA was extracted from 200 mg of faecal sample as 
previously described (Lehtinen et al., 2018).
Please cite this article as 'in press'  Beneficial Microbes 
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Samples were analysed by real-time quantitative polymerase 
chain reaction (qPCR) for NCFM, Bl-04 and Lpc-37 (qPCR 
assay details in supplemental materials and Supplementary 
Table S5). All quantification was based on comparison to 
standard curves of pure target culture DNA. To determine 
a positive sample the following criteria were used: any 
individual sample signal must fall on the standard curve 
(meaning quantifiable); in cases where both baseline and 
post intervention were positive, only an increase from 
baseline would be counted as positive; any sample had to 
be positive following the above criteria in 2 out 3 of the 
assays used. Only samples from participants who delivered 
a faecal sample at both baseline and post-intervention 
were analysed.
Statistical methods
Detailed description of statistical analyses are presented 
in the Supplementary Materials and methods. In brief, the 
primary analyses were performed for two different study 
populations: The intention-to-treat (ITT) population and 
per-protocol (PP) population. ITT was considered the 
primary efficacy analysis population. In case of missing 
data, last observation carried forward method be applied 
to conduct the statistical analysis for the ITT population.
The primary efficacy analysis for abdominal bloating 
followed the multivariate approach (ANCOVA) controlling 
for baseline on the average VAS score for the change from 
baseline (day -7 to 1) to treatment period (day 7 to 13).
The secondary efficacy analyses for digestive symptoms 
in addition to bloating, CTT, PAC-SYM, PAC-QoL and 
number of defecations followed the same multivariate 
approach (with discrete PAC variables also non-parametric 
analysis was conducted). In addition, the BSS scores 
were categorised as constipation (1,2); optimal (3,4,5); or 
diarrhoea (6,7), and were compared with a chi-square test 
for homogeneity. McNemar’s test was used to analyse how 
many participants moved between the categories. Overall 
product satisfaction was assessed at day 14 with a 5-point 
ordinal Likert scale (1 to 5) and evaluated using chi-square 
tests of homogeneity between the groups.
A post-hoc analysis was conducted to determine the 
differences in subgroups regarding VAS items (bloating, 
flatulence, abdominal pain, and burbling), CTT and bowel 
movement frequency. CTT and faecal microbial data 
(qPCR) were investigated further to define five subgroups 
for the post-hoc analysis: (1) ITT; (2) PP; (3) PP + CTT 
extremes excluded (PP + CTT); (4) PP + qPCR non-
compliants excluded (PP + qPCR); (5) PP + CTT extremes 
excluded + qPCR non-compliants excluded (PP + CTT + 
qPCR). A few participants were found to have abnormal 
CTT values (less than 24 hours or more than 100 hours 
during the treatment period), thus these participants were 
excluded from the subgroup 3. The qPCR results were 
used to ensure that the IP were properly consumed, thus 
additional subgroups 4 and 5 were formed.
Repeated measurement models (for VAS values), Wilcoxon 
two-sample test (for CTT and AUCs describing the changes 
in VAS items) and generalised linear models (time to 
significant relief, bowel movement frequency) were used 
in the post-hoc analyses.
3. Results
Participants
In total, 264 participants were screened and 263 were 
enrolled into the study after receiving their voluntarily 
signed informed consent. A total of 156 of the randomised 
participants were treated with IP (78 with active and 78 
with placebo treatment) and included in the safety analysis 
population. The ITT and PP populations comprised of 
156 and 102 participants, respectively. Figure 2 shows 
the distribution of participants, including entries and 
withdrawals from this study in a CONSORT flow diagram. 
All 156 participants in the ITT population met the eligibility 
criteria at screening and there were no missing data for these 
criteria. Participants were assigned to a treatment group 
based on the administered treatment. The randomisation 
code was not broken for any of the participants during 
the study. Unblinding of the randomisation code occurred 
after database lock.
Safety results
There were no AEs reported that were probably or definitely 
related to the active or placebo treatment. The summary of 
AEs is presented in Supplementary Table S2. There were 
no clinical safety concerns with study product, no events 
leading to death and no SAEs were reported in this study. IP 
consumption was discontinued for two participants because 
of the administration of antibiotic treatment following an 
AE: one participant in the active group had a tooth abscess 
and one participant in the active group had Herpes simplex. 
There were no clinically significant abnormal vital signs, 
physical findings or other observations related to study.
Subjective assessment of digestive symptoms
No statistically significant differences were observed 
between the two treatment groups in the primary efficacy 
analysis for self-reported bloating. The mean VAS score 
for abdominal bloating at baseline in the ITT population 
was similar (P=0.925) in the two treatment groups and the 
mean change from baseline to treatment was also similar 
(P=0.965) in the two groups (Supplementary Table S3). 
 Please cite this article as 'in press'
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6 Beneficial Microbes ##(##)
This change from baseline to treatment was negative, 
showing that the symptom scores were decreasing. In 
the PP population, the mean average bloating VAS scores 
at baseline demonstrated a slightly larger, although not 
statistically significant (P=0.366), difference than in the 
ITT population, and the mean change from baseline 
to treatment was similar (P=0.986) in the two groups 
(Supplementary Table S3). The treatment difference for 
change scores (controlling for baseline) was not statistically 
significant in ITT (P=0.987) or PP (P=0.766) populations 
(Supplementary Table S3). The secondary efficacy analysis 
of flatulence, abdominal pain, and burbling, showed no 
statistically significant treatment effects in the ITT nor 
PP populations (Supplementary Table S3). The results of 
the cohort analysis were consistent with the main analysis.
Post-hoc analysis of subjective digestive symptoms, AUC 
values, were investigated. Improvements on the VAS scale 
have negative values, but for clarity were inverted to be 
positive as AUC values. The placebo and active groups did 
not differ in bloating, abdominal pain or burbling in any 
of the subgroups on day 7 and 14. However, there was a 
statistically significant difference in flatulence in ITT, PP, 
and PP + qPCR subgroups on day 7 (P-values 0.0313, 0.0253 
and 0.0222, respectively) and day 14 (P-values 0.0116, 0.0102 
and 0.0090, respectively) (Figure 3). The difference was in 
favour of the active group resulting in larger positive AUC 
values, i.e. lower flatulence VAS values, than in the placebo 
group. There were statistically significant differences also in 
the mean of all VAS measurements in favour of the active 
group on day 7 (ITT, P=0.0425) and day 14 (ITT, P=0.0208; 
PP, P=0.0438). The repeated measurements analysis results 
were in line with the non-parametric AUC results.
Colonic transit time
Not all participants consumed 100% of radio-opaque 
markers within the given time-window, therefore 
adjustments were needed in the CTT calculations (Ibarra 
et al., 2017). There was no statistically significant evidence 
of a treatment effect on CTT in the ITT or PP populations 
(Supplementary Table S3), and the results of the cohort 
Screened for eligibility
              (n=264)
Enrollment
  (n=263)
Excluded
Did not provide consent (n=1)
Excluded:
Not eligible (n=79)
Withdrawal (n=8)
Lost to follow-up (n=7)
Adverse event (n=7)
Laboratory adverse event (n=1)
Other (n=6)
Randomisation
      (n=156)
ITT population
Placebo (n=78)
ITT population
Active (n=78)
PP population
Placebo (n=50)
PP population
Active (n=52)
Discontinued
Adverse event (n=2)
Discontinued:
Protocol deviation (n=2)
Figure 2. Disposition of participants in a CONSORT flow diagram. The demographic and physical characteristics of the two 
treatment groups in the intention-to-treat (ITT) population were similar (Supplementary Table S1), and there were no notable 
differences in demographics between the ITT and the per-protocol (PP) population. The physical activity level in both groups did 
not change during the study according to the international physical activity questionnaire results, and there were almost equal 
number of subjects within each activity level at baseline and post-intervention.
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analysis were consistent with the main analysis. At baseline, 
all groups had CTTs in line with other studies looking at 
constipated subjects (Miller et al., 2017c) (Supplementary 
Table S3). The post-hoc analysis of CTT did not reveal 
any statistically significant differences between treatment 
groups, although in all subgroups the transit times were 
slightly shorter in the active group than in the placebo 
group on day 14 (Supplementary Figure S1).
Defecation frequency and stool consistency
Primary analysis showed no statistically significant evidence 
for treatment effect on defecation frequency in the ITT or 
PP populations (Supplementary Table S3) and the cohort 
analyses were consistent with the main analysis. According 
to the primary analysis, there was no statistically significant 
difference between the number of participants in each 
stool consistency category (constipation, optimal and 
diarrhoea) from baseline to treatment or from run-in to 
on-treatment (Supplementary Table S3). There were no 
significant differences between treatment groups in the 
number of participants transitioning between categories. 
The post-hoc analysis of bowel movement frequency from 
adjusted analysis revealed statistically significant difference 
(P=0.0453) between treatment groups in PP + CTT + qPCR 
subgroup favouring active group over placebo group. 
Bowel movement frequency was also explored post-hoc 
in connection with stool consistency, using event count 
before treatment and in both treatment weeks. This analysis 
showed that in both treatment groups, the consistency of 
stool was improved from constipation to optimal category. 
However, there was no difference between the treatment 
groups.
PAC-SYM and PAC-QoL questionnaires
There was no statistically significant evidence of a treatment 
effect on PAC-SYM or PAC-QoL questionnaires in the 
ITT population (Supplementary Table S3). The results 
for the PP population were consistent with those for the 
ITT population and the results of the cohort analysis were 
consistent with the main analysis.
Overall product satisfaction
There was no statistically significant difference between 
the product rating in the two treatment groups in the 
ITT population (Supplementary Table S3). The results 
for the PP population were consistent with those for the 
ITT population and the results of the cohort analysis were 
consistent with the main analysis.
Faecal recovery
Faecal microbial member abundance was analysed by qPCR 
as an exploratory parameter for determining probiotic 
recovery. A total of 264 samples from 132 participants (64 
in the active group, 68 in the placebo group) with baseline 
and post-intervention timepoints were measured. Based 
on the detection of NCFM, Bl-04 and Lpc-37 in faeces, 
71.7% of the active group were positive – according to 
the pre-defined criteria – and 93.5% of the placebo group 
were negative (Figure 4, Supplementary Table S4). Overall, 
the study had good probiotic recovery based on microbial 
qPCR analysis.
100
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-40
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Flatulence Mean of all VAS
Placebo
Active group
P=0.0313
P=0.0116
P=0.0253
P=0.0208
P=0.0222
P=0.0090
P=0.0425
P=0.0102 P=0.0438
P=0.0742 P=0.1475
P=0.0886
Day 7 Day 14 Day 7 Day 14 Day 7 Day 14 Day 7 Day 14 Day 7 Day 14 Day 7 Day 14
ITT PP PP+qPCR ITT PP PP+qPCR
Figure 3. Average area under the curve (AUC) values for flatulence and mean of all digestive symptoms (baseline and treatment) in 
subgroups intention-to-treat (ITT), per-protocol (PP) and PP + qPCR non-compliants excluded (PP + qPCR) (day 7 and 14). Subjects 
showing improvement on the visual analogue scale (VAS) have negative values, which were inverted for clarity as AUC values.
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4. Discussion
Given the promising clinical effects of probiotics on 
gastrointestinal health to date, the objective of this clinical 
study was to evaluate the efficacy and safety of the two-
week supplementation of a probiotic blend on bloating, 
CTT and other gastrointestinal symptoms in adults with 
self-reported bloating and constipation. The study had a 
randomised, double-blind, placebo-controlled design to 
minimise bias when comparing safety and efficacy data 
between the treatments. The strains NCFM, Lpc-37, Bl-04, 
Bi-07, and HN019 have previously been tested in clinical 
trials with efficacy shown in the digestive and immune 
health related areas, and are currently commercialised 
worldwide as dietary supplements. The dosages used in 
this trial have been proven safe for human consumption 
and in the clinical trials conducted with these strains, there 
have been no SAEs related to the IP or the trial procedures. 
No IP-related AEs or SAEs were reported in this study 
either, confirming the previously reported safety of these 
lactobacilli and bifidobacterial strains. In addition, there 
were no clinically significant abnormalities in vital signs 
or physical findings related to safety of the study product.
The randomisation of the study population was successful, 
and there were no notable differences in the baseline 
characteristics between the active and placebo group. 
FFQ was assessed only at the beginning of the trial to 
evaluate the fulfilment of the inclusion criteria. Since the 
management of constipation-related symptoms is often 
focused on lifestyle and diet, these variables could have been 
evaluated further. Regarding physical activity, a component 
possibly affecting digestive discomfort and transit time, 
there were no observed differences between the two study 
populations. Smoking status can affect digestive symptoms 
and especially quitting smoking has been reported to cause 
constipation (Hajek et al., 2003). More current smokers 
were reported in the active group than in the placebo group. 
However, the number of ex-smokers was similar between 
groups. The primary results were similar in ITT and PP 
populations, even though a considerably high number 
of participants were excluded from PP population due 
to screening failures, withdrawals, and major protocol 
deviations. The observed results for product recovery 
in faeces by qPCR are in accordance for probiotic trials 
(Lehtinen et al., 2018). This however, to the best of our 
knowledge, is the first multi-strain probiotic recovery 
reported in humans.
In primary analysis, the results for active and placebo 
were similar in this study. Our study population was 
not expressing as severe bloating as would have been 
expected from previously reported studies with constipated 
populations, where the pooled bloating severity was 3.0 
(Fateh et al., 2011; Waitzberg et al., 2013). The inclusion 
limit for self-reported bloating was set to at least two 
bloating events per week, and the baseline value for 
bloating severity in our study population was 1.96. This 
may partly explain why we did not observe any significant 
improvement in the bloating severity in this trial, i.e. the 
study population was not bloated enough to allow for a 
substantial improvement. The effects of probiotics on 
bowel movement frequency are reported to be greater in 
studies where functional constipation was diagnosed using 
Rome III, compared to non-Rome diagnosis techniques 
(Miller et al., 2017c). Also, in our study, we based the 
inclusion criteria to functional constipation or IBS-C by 
Rome III and verified the fulfilment of these criteria from 
the participants’ self-assessment. Besides Rome III, other 
criteria, such as 1-3 bowel movements per week and stool 
consistency 1-2 on the BSS for most (≥50%) spontaneously 
passed stools, were selected in order to narrow down the 
population to those suffering from functional constipation 
and slow transit time. Miller et al. (2017b) reported pooled 
estimates for normative values in constipated population 
for stool frequency (2.7 weekly stools) and form (2.4 in BSS) 
according to Rome III criteria. The normative value for 
pooled CTT (58 hours) has also been reported by Miller et 
al. (2017a) in a systematic review and meta-analysis. CTT 
differ from person to person; on average, the CTT for a 
healthy individual is between 30-40 hours on average but 
can range to 70 hours (Bautista Casasnovas et al., 1991; 
Kim and Rhee, 2012; Metcalf et al., 1987). The newly 
published method for correction for non-compliance when 
determining CTT (Ibarra et al., 2017) was implemented in 
this study, which added more accuracy in this evaluation. In 
the light of these expected normative baseline values, our 
ITT population – with 2.4 bowel movements per week, stool 
form 2.0 in BSS, and 66 hours’ transit time – was suffering 
from functional constipation, albeit we did not observe 
significant changes in any of these outcomes.
A high placebo effect and the relatively short duration 
of the study could have contributed to the null primary 
analysis results. A strong placebo effect is common in 
many probiotic studies, especially in those involving 
71.7% 6.5%
Active Placebo
qPCR positive qPCR negative
Figure 4. Multi-strain product recovery analysed by quantitative 
polymerase chain reaction (qPCR).
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participants’ self-evaluation of their symptom severity. 
Interestingly, there are other studies reporting beneficial 
effects of probiotics, especially HN019, already after two 
to four weeks’ consumption. A study by Waller et al. (2011) 
reported significant improvements in CTT and frequency 
of functional GI symptoms already in two weeks in adult 
population diagnosed with constipation (Waller et al., 
2011). A more recent 28-day intervention with HN019 
did not reveal any clear relief in transit time, but instead a 
physiologically relevant increase in weekly bowel movement 
frequency was observed in those participants who had fewer 
than three bowel movements per week initially (Ibarra et 
al., 2018). Moreover, there seems to be evidence that longer 
interventions (60-105 days) may be required to determine 
the effects of probiotics on constipation symptoms (Riezzo 
et al., 2018). The study by Waller et al. (2011) indicated 
that daily supplementation with HN019 for 14 days could 
decrease CTT dose-dependently. With respect to our study, 
a similar effect was not seen with a five-probiotic strain 
combination in two weeks, even though the total dose used 
was slightly higher than in the reference studies; 1010 cfu/
day of HN019 and a total count of 2.75×1010. Waller and co-
workers (2011) used two dosages of HN019: 1.72×1010 cfu/
day and 1.8×109 cfu/day, while Ibarra et al. (2018) reported 
109 and 1010 cfu/day.
The additional post-hoc analysis revealed some differences 
between the probiotic and placebo treatments. A statistically 
significant difference between treatment groups in the 
severity of flatulence, measured with AUC, was noted 
on both study weeks in ITT and PP populations and in 
the PP subgroup, from which the qPCR non-compliants 
were removed. Moreover, the means of all the VAS scores 
also favoured the active group, indicating a possible trend 
toward symptom improvement. However, the differences 
of the means are only approximately 4-5% of the whole 
range of AUCs.
There were no differences found in CTT in any of the 
subgroups. However, there was some statistical evidence 
of greater increase in bowel movement frequency for active 
probiotic treatment in PP + CTT + qPCR subgroup, but 
the confidence interval was rather wide. Thus, one must 
be cautious when drawing conclusions of the effect of 
the study product to bowel movement frequency. While 
investigating the digestive symptoms post-hoc, one must 
remember that AUCs behave somewhat differently than 
the absolute symptom scores, as it is a cumulative analysis. 
Nonetheless, the post-hoc analysis revealed statistically 
significant differences in flatulence and mean VAS of all 
symptoms in the ITT and PP populations. Significant 
relief in flatulence was also observed in the PP subgroup 
from which the qPCR non-compliants were removed. 
This subgroup was the most compliant to the product 
consumption in terms of product recovery. Using the mean 
VAS besides the individual symptoms seems to be a valid 
addition providing information on symptoms’ evolution 
on a general level.
In conclusion, although there were no differences in the 
primary analysis, the combination of five tested lactobacilli 
and bifidobacteria strains was well tolerated and safe to 
consume. In addition, the two-week consumption of this 
probiotic blend seemed to improve the self-reported 
digestive symptoms, especially flatulence, in adults with 
self-reported bloating and constipation.
Supplementary material
Supplementary material can be found online at https://doi.
org/10.3920/BM2018.0163.
Supplementary Materials and methods
• Ethics and good clinical practices
• Exclusion criteria
• Investigational product
• qPCR assays
• Statistical methods
Table S1. Demographic and baseline characteristics of the 
intention-to-treat population.
Table S2. Summary of adverse events.
Table S3. Mean values of primary and secondary outcomes 
in intention-to treat and per-protocol populations.
Table S4. Faecal recovery qPCR results, shown as 
qualitatively positive by assay and, the criteria of being 
positive for 2 out of 3 or 3 out of 3 of the assays concurrently.
Table S5. Primer sequences and annealing temperatures.
Figure S1. eDiary average response curves in different 
subgroups: ITT, PP, PP + CTT, PP + qPCR, and PP + CTT 
+ qPCR.
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